MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

OnabotulinumtoxinA (Botox®)

Selected References:

  • Bodkin CL, et al. 2005. OnabotulinumtoxinA therapy during pregnancy. Mov Disord 20(8): 1081-1082.
  • Briggs J, et al. 2005. Drugs in pregnancy and lactation, 7th 174-175. Lippincott Williams & Wilkins: Philadelphia.
  • Brin MF, et al. 2016. Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiology and Drug Safety. 25: 179–187.
  • Brin, MF, et al 2023. Pregnancy outcomes in patients exposed to onabotulinumtoxinA treatment. Neurology. 101: e103-e113.
  • Cardon BR, Smith ME, Cerrati EW. 2021 May-June. Case Series of Botulinum Toxin Administered to Pregnant Patients and Review of the Literature. Facial Plast Surg Aesthet Med. 23(3):187-190.
  • De Oliveira Monteiro E. 2006. Botulinum toxin and pregnancy. Skinmed 5(6): 308.
  • Li Yim and Weir CR. 2010. Botulinum toxin and pregnancy – cautionary tale. Strabismus 18(2): 65-66.
  • Morgan JC, et al. 2006. Botulinum toxin A during pregnancy: a survey of treating physicians. J Neurol Neurosurg Psychiatry 77 (1) 117-119.
  • Newman W.J., et al 2004. OnabotulinumtoxinA therapy during pregnancy. Mov Disord 19(11): 1384-1385.
  • Polo JM, et al. 1996. Botulism and pregnancy. Lancet 348: 195.
  • Robinson AY, Grogan PM. OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report. Mil Med. 2014 Jun;179(6):e703-4.
  • Clair EH, et al. 1975. Observations of an infant born to a mother with botulism. J Pediatr 87: 658.
  • Wataganara T, et al. 2009. Treatment of severe achalasia during pregnancy with esophagoscopic injection of botulinum toxin A: a case report. J Perinatol 29(9): 639.
  • Wong HT, et al. 2020. OnabotulinumtoxinA for chronic migraine during pregnancy: a real-world experience on 45 patients. J Headache Pain. 21(1):129.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.